Roche Holding is trading at CHF 355.00 (+3.14%), with the catalyst still unclear.
- The stock is rising despite a weaker overnight risk tone and lower U.S. futures.
- No fresh September 14, 2026 company-specific catalyst was identified.
- Recent coverage highlights FDA clearance for Roche and Eli Lilly’s Alzheimer’s blood test, announced August 24, but does not directly link it to this move; monitor for delayed Swiss-market or analyst headlines.